Aβ1-42 reduces P-glycoprotein in the blood-brain barrier through RAGE-NF-κB signaling

Cell Death and Disease

Volumn 5, Issue 6, 2014, Pages

  Park, R ^a   Kook, S Y ^a   Park, J C ^a   Mook Jung, I ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN[1-42]; GLUCOSE TRANSPORTER 1; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NEUTRALIZING ANTIBODY; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); IMMUNOGLOBULIN RECEPTOR; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTE CULTURE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CELL CONTACT; CELL POLARITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; HIPPOCAMPUS; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WILD TYPE; ANIMAL; BIOSYNTHESIS; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; DOWN-REGULATION; ENDOTHELIAL CELLS; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; NF-KAPPA B; P-GLYCOPROTEIN; PEPTIDE FRAGMENTS; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 84903761512     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.258     Document Type: Article

References (46)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
3. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010; 330: 1774.
4. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008; 18: 253-266.
5. Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the bloodbrain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 2007; 24: 1745-1758.
6. Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. Prog Drug Res 2003; 61: 39-78.
7. Neuwelt EA. Mechanisms of disease: the blood-brain barrier. Neurosurgery 2004; 54: 131-140; discussion 141-132.
8. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-185.
9. Wardlaw JM, Sandercock PA, Dennis MS, Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 2003; 34: 806-812.
10. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201.
11. Demeule M, Labelle M, Regina A, Berthelet F, Beliveau R. Isolation of endothelial cells from brain, lung, and kidney: expression of the multidrug resistance P-glycoprotein isoforms. Biochem Biophys Res Commun 2001; 281: 827-834.
12. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997; 8: 161-170.
13. Hayashi Y, Nomura M, Yamagishi S, Harada S, Yamashita J, Yamamoto H. Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes. Glia 1997; 19: 13-26.
14. Gaillard PJ, van der Sandt IC, Voorwinden LH, Vu D, Nielsen JL, de Boer AG et al. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm Res 2000; 17: 1198-1205.
15. Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ et al. beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem 2001; 76: 1121-1128.
16. Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I et al. MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides-implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 2007; 17: 347-353.
17. Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W et al. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002; 12: 535-541.
18. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 2005; 115: 3285-3290.
19. Hartz AM, Miller DS, Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharmacol 2010; 77: 715-723.
20. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006; 26: 10129-10140.
21. Moon M, Hong HS, Nam DW, Baik SH, Song H, Kook SY et al. Intracellular amyloid-beta accumulation in calcium-binding protein-deficient neurons leads to amyloid-beta plaque formation in animal model of Alzheimer's disease. J Alzheimers Dis 2012; 29: 615-628.
22. Kalaria RN. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann N Y Acad Sci 1999; 893: 113-125.
23. Kania KD, Wijesuriya HC, Hladky SB, Barrand MA. Beta amyloid effects on expression of multidrug efflux transporters in brain endothelial cells. Brain Res 2011; 1418: 1-11.
24. Wijesuriya HC, Bullock JY, Faull RL, Hladky SB, Barrand MA. ABC efflux transporters in brain vasculature of Alzheimer's subjects. Brain Res 2010; 1358: 228-238.
25. Kook SY, Hong HS, Moon M, Ha CM, Chang S, Mook-Jung I. Abeta(1)(-)(4)(2)-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca(2)(+)-calcineurin signaling. J Neurosci 2012; 32: 8845-8854.
26. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685-691.
27. Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P et al. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med 1995; 1: 693-699.
28. Ohkita M, Takaoka M, Shiota Y, Nojiri R, Sugii M, Matsumura Y. A nuclear factor-kappaB inhibitor BAY 11-7082 suppresses endothelin-1 production in cultured vascular endothelial cells. Jpn J Pharmacol 2002; 89: 81-84.
29. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005; 83: 876-886.
30. Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 2004; 35(11 Suppl 1): 2628-2631.
31. Li M, Shang DS, Zhao WD, Tian L, Li B, Fang WG et al. Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. J Immunol 2009; 182: 5778-5788.
32. Kim JH, Kim JH, Park JA, Lee SW, Kim WJ, Yu YS et al. Blood-neural barrier: intercellular communication at glio-vascular interface. J Biochem Mol Biol 2006; 39: 339-345.
33. Brenn A, Grube M, Peters M, Fischer A, Jedlitschky G, Kroemer HK et al. beta-Amyloid downregulates MDR1-P-glycoprotein (Abcb1) expression at the blood-brain barrier in mice. Int J Alzheimers Dis 2011; 2011: 690121.
34. Mincheva-Tasheva S, Soler RM. NF-kappaB signaling pathways: role in nervous system physiology and pathology. Neuroscientist 2013; 19: 175-194.
35. Gonzalez-Velasquez F, Reed JW, Fuseler JW, Matherly EE, Kotarek JA, Soto-Ortega DD et al. Activation of brain endothelium by soluble aggregates of the amyloid-beta protein involves nuclear factor-kappaB. Curr Alzheimer Res 2011; 8: 81-94.
36. Bierhaus A, Humpert PM, Stern DM, Arnold B, Nawroth PP. Advanced glycation end product receptor-mediated cellular dysfunction. Ann N Y Acad Sci 2005; 1043: 676-680.
37. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000; 275: 25781-25790.
38. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 2006; 1: 223-236.
39. Lafon-Cazal M, Adjali O, Galeotti N, Poncet J, Jouin P, Homburger V et al. Proteomic analysis of astrocytic secretion in the mouse. Comparison with the cerebrospinal fluid proteome. J Biol Chem 2003; 278: 24438-24448.
40. Skalnikova H, Motlik J, Gadher SJ, Kovarova H. Mapping of the secretome of primary isolates of mammalian cells, stem cells and derived cell lines. Proteomics 2011; 11: 691-708.
41. Merlini M, Meyer EP, Ulmann-Schuler A, Nitsch RM. Vascular beta-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAbeta mice. Acta Neuropathol 2011; 122: 293-311.
42. Yang J, Lunde LK, Nuntagij P, Oguchi T, Camassa LM, Nilsson LN et al. Loss of astrocyte polarization in the tg-ArcSwe mouse model of Alzheimer's disease. J Alzheimers Dis 2011; 27: 711-722.
43. Dahlgren KN, Manelli AM, Stine Jr WB, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002; 277: 32046-32053.
44. Dallaire L, Tremblay L, Beliveau R. Purification and characterization of metabolically active capillaries of the blood-brain barrier. Biochem J 1991; 276(Pt 3): 745-752.
45. Benavides A, Pastor D, Santos P, Tranque P, Calvo S. CHOP plays a pivotal role in the astrocyte death induced by oxygen and glucose deprivation. Glia 2005; 52: 261-275.
46. Kuchler-Bopp S, Delaunoy JP, Artault JC, Zaepfel M, Dietrich JB. Astrocytes induce several blood-brain barrier properties in non-neural endothelial cells. Neuroreport 1999; 10: 1347-1353.